NCT01928940View on ClinicalTrials.gov

Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 15, 2013

Primary Completion Date

September 18, 2014

Study Completion Date

July 4, 2016

Conditions
Solid Tumours
Interventions
DRUG

dabrafenib

150 mg twice daily

DRUG

trametinib

2 mg once daily

Trial Locations (2)

411-8777

GSK Investigational Site, Shizuoka

104-0045

GSK Investigational Site, Tokyo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01928940 - Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part) | Biotech Hunter | Biotech Hunter